Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643355 · ClinicalTrials.gov registry record · NA
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT02643355: Completed NA study, sponsored by Hennepin Healthcare Research Institute.
NCT02643355 is a NA study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02643355, a NA study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic that is given frequently in the ED for many of the same symptoms that are seen in patients who are experiencing opioid withdrawal, however its use in this toxidrome has never been studied. The hypothesis of this study is that olanzapine is a safe and efficacious option when compared to clonidine for the treatment of opioid withdrawal in the emergency department.
Primary Outcome
Rescue Medication (additional medications given for symptoms) within 1 hour of medication administration
Interventions
- DRUG Olanzapine
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06-21 |
| Phase | NA |
What the finished NCT02643355 record still lists
NCT02643355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT02643355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02643355 about?
NCT02643355 is a clinical study titled "Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED". Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid wi...
What is the current status of trial NCT02643355?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2015-11. Estimated completion is 2017-06-21.
What interventions are being tested in trial NCT02643355?
The interventions under investigation include: Olanzapine (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT02643355?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02643355's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia